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Abstract 
This study’s aims were to evaluate the effects of Sorensen’s Therapy of Instability in Mood 
(Sorensen, 2005; Sorensen, Done & Rhodes, 2007), an intervention based on a short 
relapse-prevention program for clients suffering from Bipolar Disorder (BD), delivered 
within a clinical setting, by an assistant psychologist with limited training in CBT. The 
experimental treatment consisted of four individual sessions in addition to treatment as 
usual. Twelve clients with diagnoses of BD participated. Outcomes were measured 
across four domains: symptom severity, perceived hopelessness, perceived control over 
symptoms and level of insight. Measures of client satisfaction were also collected. 
Statistical analysis of the data revealed significant improvements to depression and 
perceived control levels at both one and three month follow-ups. In addition, clients 
reported significantly lower levels of hopelessness at three months follow-up. The study 
also considered the clinical significance of the research findings with the Jacobson-Truax 
(Jacobson & Truax, 1991) method. A substantial number of clients attained clinically 
significant changes with regards to depression, hopelessness and perceived control at 
one and three months follow-ups. Recovery rates at three months were 50%, 41.6% and 
25% respectively. Neither statistically nor clinically significant changes were found with 
regards to mania or insight at either one or three month follow-ups. All clients reported 
high levels of satisfaction. 
 
Keywords: Cognitive-behavioural therapy, psycho-education, brief intervention relapse 
prevention, bipolar disorder, clinical significance analysis and single case design. 
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Introduction  
 
Bipolar disorder (BD) is a recurrent condition characterised by extreme changes in 
mood and is associated with significant morbidity and mortality. Annual prevalence 
rates in the year 2004 have been reported to be between 1.3% and 2% in the UK 
(Regeer et al., 2004). Subsyndromal symptoms, mainly depression and significant 
psychosocial deficits such as poor work adjustment are often reported (Post et al., 
2003). BD seldom occurs in the absence of other mental health problems and has been 
associated (more than any other psychiatric disorder) with heightened suicidality 
(Miklowitz & Johnson, 2006; Newman, 2005): One in four people diagnosed with BD 
attempt suicide (Dalton, Cate-Carter, Mundo, Parikn & Kennedy, 2003). Indeed suicidal 
ideation is frequent and around 15% of BD patients commit suicide (McIntyre et al., 
2008). 
 
The burden of suffering is not restricted to the patient, but also impacts on the family. 
Almost 60% of BD sufferers divorce or separate and most clients tend to have significant 
long term disability and impaired occupational and social functioning (Michalak, 
Yatham & Lam, 2005; Michalak, Yatham, Maxwell, Hale & Lam, 2007; Simon, Ludman, 
Unutzer, Operskalski & Bauer, 2008). The economic costs resulting from BD are 
considerable and estimated to have cost the UK £2 billion in 2001 (Das Gupta & Guest, 
2002).  
 
The main treatment modality has been pharmacotherapy; however, despite its 
efficacy in treating the acute phase of the illness, many patients experience multiple 
relapses. Further, the positive results obtained in clinical trials of medication have not 
been replicated in clinical practice and the medical approach working in isolation 
has significant limitations at both symptomatic and functional levels, as illustrated by 
the lack of long-term effectiveness and non-adherence (Greenhouse, Meyer & 
Johnson, 2000; Huxley, 2002; Keck, McElroy, Strakowski, Bourne & West, 1997; Kessler 
et al., 1997; Nilson, 1999). In a longitudinal study Gitlin, Swendsen, Heller and 
Hammen (1995) found a relapse risk of 37% after one year and 73% after five or more 
years for patients on continual mood-stabilizing medication.  
 
Medical intervention alone therefore has been unable to meet the wider needs of 
patients with BD and as a result, an increased interest in the benefits of adjunctive 
psychosocial approaches emerged. Cognitive Behavioural Therapy (CBT), 
Psychoeducational Interventions (PE), Family Therapy and Interpersonal and Social 
Rhythm Therapy (IPSRT) have been found to be valuable when combined with 
pharmacotherapy in the treatment of BD in randomised control trials (RCTs) (Colom, 
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Vieta, Martinez-Aran et al., 2003; Lam et al., 2000; Lam et al., 2003; Scott, Garland & 
Morhead, 2001). Evidence suggests that, at least for a subgroup of clients, better 
outcomes are achieved when psychosocial interventions are added to 
pharmacotherapy (Ibid). However, the clinical reality for most users of the National 
Health Service is that despite all the years of research, the treatment for this illness is, 
still predominantly pharmacological.  
 
Several reasons can be considered to account for this. For a start, the resources 
available in research are different from those in the mental health service and the 
benefits observed in the ‘laboratory’ setting are often not transmitted to real life 
clinical practice. Except for a few psychosocial interventions (Cochran, 1984; Perry, 
Tarrier, Morris, McCarthy & Limb, 1999) the majority of approaches are delivered by 
highly skilled clinicians with many years of experience (Lam et al., 2003; Miklowitz et 
al., 2000; Scott et al., 2006) and even where manuals are available detailing the 
steps of an intervention, this tends to be insufficient. The complexity of the approach 
normally requires the provision of supervision and training, usually delivered through 
training centres to ensure that the clinician becomes a competent practitioner in the 
delivery of a particular approach. Many approaches are delivered over long periods 
of time, often between 20 and 30 sessions over a minimum of six months (Lam, Jones, 
Hayward & Bright, 1999; Miklowitz et al., 2000). Providing these long term interventions 
within Community Mental Health Teams and Psychology services is a challenge 
when considering that most already struggle with long waiting lists and limited staff 
resources. 
 
The reality is that most people with BD do not receive any form of therapy for the 
reasons stated above and those who have in the past, are often participants in 
research programs and only do so after many years of having received a diagnosis of 
BD. There is no doubt, that psychological interventions for BD need to be effective, 
but to be applicable to clinical practice they also need to match the resources 
available in today’s health care system. Some authors advocate the use of brief 
interventions that can be delivered by less skilled or less experienced professionals in 
shorter periods of time and indeed the value of shorter interventions (4 to 12 sessions) 
has been shown in some RCTs. Cochran (1984) was among the first to demonstrate 
that 6 sessions of a CBT programme whose main aim was to increase compliance 
with medication was a very cost effective intervention. Later Perry and colleagues 
(1999) also promoted a short intervention based exclusively on relapse prevention. 
More recently, Sorensen developed an intervention based on a short relapse-
prevention program named The Sorensen Therapy for Instability in Mood (STIM) 
(Sorensen, 2005; Sorensen, Done & Rhodes, 2007). A major advantage of this brief 
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intervention is that it is designed to be delivered by staff with very little training in CBT. 
These are important factors that make this intervention easily applied and delivered 
to clients with BD, and therefore of special interest for pressured and often under 
resourced NHS Psychology Services.  
 
There has been only one study (Sorensen et al. 2007), which evaluated the feasibility 
of this program with 13 BD clients. The results were positive and promising, however 
the intervention was delivered by an experienced psychologist, and therefore the 
claim that it can be administered by less experienced clinicians has yet to be 
confirmed. The study reported here aimed to evaluate the effects and acceptability 
of STIM (Sorensen, 2005) when it is delivered as an adjunct to pharmacotherapy to 
patients suffering from BD by staff with limited training in CBT (such as Assistant 
Psychologists) and within a clinical setting. 
 
The Sorensen Therapy for Instability in Mood (STIM)  
 
STIM consists of four individual sessions of a relapse prevention programme, delivered 
in most cases over four consecutive weeks by an Assistant Psychologist. Sessions last 
for 50 minutes. Session one helps the client develop a better understanding of BD in 
general terms and in relation to their personal experience of it. The stress-vulnerability 
framework, developed by Zubin and Spring (1977) is described in order to 
differentiate between what may cause an initial episode of BD and factors which 
influence the likelihood of future relapse into an illness episode. The aims of sessions 
two and three are to increase the client’s awareness of early signs, symptoms and 
triggers for both depressive and manic episodes and the identification of an 
individual symptom profile as well as discussing coping strategies. In session four, the 
illness management strategies agreed in previous sessions are integrated and applied 
to the client’s work and social related activities. Each client is given a handbook to 
complete during the therapy sessions summarising the main aspects of the therapy 
and is encouraged to continue using them after termination of the therapy. 
 
Method  
 
Inclusion/exclusion criteria  
 
Clients were included in the study if they were aged 18 years or older, fulfilled 
diagnosis of BD I or BD II according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV)(APA, 2000) or the International Statistical Classification of 
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Diseases and Related Health Problems (ICD-10)(WHO,1990), were able to give 
informed consent and were fluent in English. Clients were excluded if they had a 
primary substance abuse disorder, were suffering from an organic brain syndrome or 
were receiving psychological treatment. Clients were also excluded if they were 
considered to be in an acute state for mania, hypomania or mixed state as defined 
by Bech-Rafaelsen Mania Scale ≥ 15 (Bech, Rafaelsen, Kramp & Bolwig, 1978) and 
The Beck Depression Inventory second edition ≥ 50 (Beck, Steer, & Brown, 1996). The 
criteria for exclusion of clients in an acute state for mania was similar to that used in 
other research studies, where the effectiveness of psychosocial interventions was 
evaluated (Lam et al., 2000; Lam et al., 2003; Lam, Hayward, Watkins, Wright & 
Sham, 2005), but the criteria for acute depression differed from that employed in 
previous research (BDI >29) . It was decided that the commonly used cut off for 
depression (BDI> 29) was too low (ibid) and that if applied it would exclude a 
considerable proportion of clients with BD living in the community, who were 
reasonably stable. It was also felt that there is a need for treatments for BD clients 
presenting with significant subsyndromal symptoms and this had not been addressed 
by previous research. The final sample consisted of 12 clients. Except for one client 
(8.3%), the entire sample were taking medication (91.6%, N = 11). Of those on 
medication, 83.3% (N = 10) were on mood stabilising medication, 75% (N = 9) on 
antidepressants and 50% (N = 6) received both. Their medication was not changed 
during the treatment intervention phase, but the study did not have the resources to 
control for changes in medication during the follow up phase. Equally, no measures 
were taken of the amount of professional contact that clients may have received 
from their local mental health team during the study.  
 
Outcome measures 
 
The variables expected to be influenced by the intervention included symptoms of 
mania and depression; level of hopelessness; level of insight and degree of control 
over internal states. A measure of the level of satisfaction with the intervention was 
also employed.  
 
On entering the study participants completed a 45-minute semi-structured interview, 
which included information about their demographic characteristics, current and 
past psychiatric history and current treatments. Measures were collected by ET and 
MJG and were compiled during the pre-treatment baseline period, three times over 
five weeks and an average score was then computed. The same measures were 
repeated at the end of session 1, mid treatment (after session 2), at the end of 
treatment (after session 4) and at one and three months follow-up.  
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The following measures were employed: the Beck Depression Inventory Second 
Edition (BDI-II) (Beck, et al., 1996), the Bech-Rafaelsen Mania Scale (BRMRS) (Bech et 
al., 1978), the Beck Hopelessness Scale (BHS) (Beck, Weissman, Lester & Trexler, 1974), 
the Insight Scale (Birchwood, Smith, Drury, & Healy, 1994), the Perceived Control 
Over Internal States (Pallant, 2000) and the Client Satisfaction Questionnaire (CSQ-8) 
(Larsen, Attkisson, Hargreaves & Nguyen, 1979). All the outcome measures above, 
are well validated and widely used in the research literature, where CBT 
interventions, for the management of BD have been employed (Scott et al., 2001; 
Lam et al., 2005; Sorensen et al., 2007).  
 
Intervention  
 
In addition to treatment as usual (TAU), clients in the study received an active 
intervention based on relapse-prevention (STIM) (Sorensen, 2005). TAU included any 
medication that the psychiatrist treating an individual client considered appropriate, 
dosages being adjusted as necessary. As part of the standard treatment individuals 
could receive support from members of the multidisciplinary community team such as 
nurses, social workers or support workers. No other form of psychological therapy was 
considered during the study period.  
 
The intervention was delivered by an Assistant Psychologist (ET), who received 
weekly supervision. She had a BSc (Hons) in Psychology and had completed a 20 
week course in basic counselling skills. As an undergraduate she gained experience 
as a health care assistant/senior support worker with various client groups in 
disparate settings working for the NHS, private health care organisations and 
charities. The AP received around eight hours of training from MJG on the relapse 
prevention model proposed by Sorensen and the rationale for it. Treatment integrity 
was ensured with the use of audio tapes and supervision. Clients were asked to give 
their consent to the audio tape of one session, chosen prior to the therapy 
commencing, Audio tapes were then analysed by the first author with the use of a 
rating scale specifically designed to measure whether the components of the session 
being evaluated had been implemented as expected.  
Data Analysis 
 
A statistical analysis of the mean differences between pre treatment and one month 
follow up and pre-treatment and three months follow up was performed with the 
paired-samples t-test, provided that the assumption of normality was met or with its 
non-parametric equivalent, the Wilcoxon signed-rank test where it was not.  
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Many researchers have advocated adding ‘clinical significance’ as a criterion for 
evaluating psychotherapy (Kazdin, 1982; Kendall, 1984; Wolf, 1978). However the 
majority of published studies rely exclusively on group means and statistical 
significance tests in evaluating treatment effects. There are two limitations with relying 
exclusively on group means. Firstly, it ignores individual variability (Barlow, 1981; 
Garfield, 1981; Hugdahl & Ost, 1981) and for clinician’s in routine practice, there is an 
interest in determining how each individual has responded to the treatment. 
Secondly, it has been accepted that changes can be statistically significant without 
being clinically meaningful (Kazdin & Wilson, 1978). 
 
 Jacobsen and colleagues developed, over a number of years, a method for 
defining clinical significance in psychotherapy (Jacobson, Follette & Revenstorf, 1984; 
Jacobson, Follette & Revenstorf, 1986; Jacobson & Revenstorf, 1988; Jacobson & 
Truax, 1991). The method which is generally referred to as the Jacobsen-Traux (JT) 
method established a two-fold criteria. First they proposed the use of a Reliable 
Change Index (RC) to determine if a change is reliable and not due to measurement 
error. This RC can be calculated with the formulae below. If the RC obtained for each 
client is greater or lesser than + / - 1.96 (depending on whether the instruments are 
positive or negative)  then one can conclude with a 95% probability (p < .05) that the 
change is reliable and not the result of an unreliable measuring instrument.  
 
diffS
xx
RC 12     1x  Client’s pre-test score 
   2x   Client’s post-test score 
 22 Ediff SS   diffS  Standard error of difference between two tests 
 
rxxsSE  11  1s  SD of the normal (functional) population 
rxx  Internal consistency of the measure 
 
Secondly, the client’s score at post-treatment has to fall within the normal population 
range, rather than within the dysfunctional population range for a clinical significant 
change to occur. JT suggested using either cut-off ‘a’, ‘b’ or ‘c’ to separate the 
functional from the dysfunctional populations. JT recommends using criterion ‘c’ if 
norms for both the functional and dysfunctional populations are available. If norms 
are not available criterion ‘a’ and ‘b’ has to be used instead. A detailed explanation 
of these three cut-off points and the equations used to calculate them is provided 
below.   
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Criterion a: Clinically significant change is achieved when the client’s level of 
functioning at post-test falls outside the range of the dysfunctional population. The 
range is defined ´as extending two standard deviations beyond (in the direction of 
functionality) the mean of the dysfunctional population’ (Jacobson et al., 1984, p. 
340).  
 
1Ma  + 12s     1M   Mean dysfunctional  
  
1s   SD dysfunctional 
 
This equation applies to positive instruments (higher scores indicative of functionality) 
when dealing with negative instruments (higher scores indicative of dysfunctional) the 
equation should be converted to:  
 
1Ma  - 12s  
 
Criterion b: Based on this criterion clinically significant change is achieved when the 
client’s level of functioning at post-test falls within the range of the functional 
population, ‘where range is defined as extending two standard deviations below the 
mean of the normal population’ (Jacobson et al., 1984, p. 340).  
 
0Mb  - 02s      0M  Mean functional  
     0s  SD functional 
 
This equation applies to positive instruments, when dealing with negative instruments 
the equation should be converted to:  
 
0Mb  + 02s  
 
Criterion c: This criterion applies when the client’s post-test score is more likely to have 
been drawn from the functional population rather than the dysfunctional group.  
 
10
0110
ss
MsMs
c



  
0M + 0s Mean and SD of the functional population
 
    11 sM  Mean and SD of the dysfunctional population  
 
Criterion ‘a’ is the most stringent criterion, criterion b is more lenient and criterion ‘c’ 
falls in between. A visual representation of these three cut-off points has been 
presented in Figure 1 below.  
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   Functional          Dysfunctional 
   population           population 
 
M0 = Mean dysfunctional population  
M1 = Mean functional population  
 
 
  
 
 
 
 
 
 
 
Figure 1. Visual Representation of Jacobson-Truax (JT) Cut-off Points for a hypothetical subject. 
 
The JT method allows for further classifying clients into categorical ratings for clinical 
improvement into Recovered, Improved, Unchanged or Deteriorated according to 
whether or not the client has met the above criteria. The clinical significance of the 
change experience by each client was analysed only for the measures where a 
statistically significant effect has been found. The data used in the calculations is 
provided in Table 1. 
 
Table 1. Data used to determine the RCI(s) and cut off points for the BDI-II, BHS and PCOISS. 
 
 
 
BDI-II  
  
BHS 
 
PCOISS 
 
Rxx 0.93 (Beck et al., 1996) 0.92 (Beck & Steer, 1988)  0.90 (Pallant, 2000) 
 
SD 
 
7.57 (Dozois et al., 1998) 
 
3.09 (Greene, 1981) 
 
12 (Pallant, 2000) 
 
0M  
 
9.11 (Dozois et al., 1998) 
 
4.45 (Greene, 1981) 
 
60.6 (Pallant, 2000) 
 
0s  
 
7.57 (Dozois et al., 1998) 
 
3.09 (Greene, 1981) 
 
12 (Pallant, 2000) 
 
1M  
 
22.45 (Beck et al., 1996) 
 
9.98 (Beck et al., 1990) 
 
 1s  
 
12.75 (Beck et al., 1996) 
 
5.42 (Beck et al., 1990) 
 
 
 
     b   c     a 
M0              M1 4
5
0
0 
a 
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Results 
 
A one way repeated-measures ANOVA was conducted to compare scores on the 
BDI-II, BMRS, BHS, Insight Scale and PCOISS across the three baselines points (B1, B2 
and B3) to investigate the stability of the measure prior to the intervention. For all 
outcome measures there was a non significant effect across time, which led to 
conclude that the assumption of independence of observation and stability of the 
behaviour has been met. The results have been illustrated in the Table 2 below. 
 
Table 2. Results of analysis across all baseline measures for all outcome measures. 
 
 
Outcome measures 
 
Wilks’ Lambda 
 
F 
 
Sig 
BDI-II 0.743 F (2, 10) = 1.727 0.227 
BMRS 0.875 F (2, 10) = 0.712 0.514 
BHS 0.872 F (2, 10) = 0.737 0.503 
Insight Scale 0.823 F (2, 10) = 1.075 0.378 
PCOISS 0.924 F (2, 10) = 0.413 0.673 
 
 
Analysis of statistical significance  
 
Statistically significant results were found for depression and perceived control over 
internal states scores between baseline and one month follow up and also between 
baseline and three months follow-up. For hopelessness scores significant differences 
with large effect sizes were found between baseline and three months follow-up, but 
not between baseline and one month follow up. For mania and for level of insight 
scores no significant differences were obtained at any stage. Table 3 and Table 4 
below present the results of this analysis.  
 
Table 3. Results of statistical analysis between baseline and 1 month follow-up. 
 
Outcome  
Measures 
         Baseline 
Mean     (SD)  
 
Median 
      1 month FU 
Mean          (SD) 
 
Median  
t/z  Sig (2-tailed) 
 
BDI-II      
 
21.86   (12.83) 
 
19.83 
 
12.92      (14.03)  
 
9.00 
 
z=-2.492 
 
0.013*  
BMRS 4.25       (2.76) 3.5 4.67          (2.77) 4.50 t =- 0.535 0.603 
BHS 9.5         (5.61) 9.83 6.83        (6.96) 4 t = 1.58o 0.143 
Insight 10.06     (1.54) 10.33 10.08        (2.06) 10.50 z = -0.178 0.858 
PCOISS 41.22   (12.40) 40.66 59.75      (15.63) 58 t =- 4.44  0.001* 
* P < 0.05 
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Table 4. Results of statistical analysis between baseline and 3 months follow-up. 
 
Outcome  
Measures 
            Baseline 
Mean         (SD)  
 
Median 
        3 month FU 
Mean          (SD) 
 
Median  
t/z  Sig (2-tailed) 
 
BDI-II      
 
21.86     (12.83) 
 
19.83 
 
10.42        (7.24)  
 
10.00 
 
t=2. 7.82   
 
0.018* 
BMRS 4.25         (2.76) 3.5 3.92          (3.47) 3.0 t= 0.263 0.797 
BHS 9.5           (5.61) 9.83 5.08          (5.31) 2.50 t= 2.708 0.020* 
Insight 10.06       (1.54) 10.33 10.33        (1.77) 10.50 z=-1.024  0.306 
PCOISS 41.22     (12.40) 40.66 59.25      (14.91) 60 t= -3.66  0.004* 
 P < 0.05 
 
Reliable Change  
 
As stated above the Reliable Change Index (RC) was calculated for the BDI-II, BHS 
and PCOISS. A summary is presented in Table 5 below with clients’ scores on the BDI-II, 
BHS and PCOISS having to show a minimum change of 5.53, 2.41 and 10.50 points 
respectively in order to demonstrate either reliable improvement or reliable 
deterioration depending in what direction the change is.  
 
The percentages and frequencies of clients achieving reliable change are shown in 
Table 5. It should be noted that not all the individuals achieving significant change 
at end of therapy or maintained their gains at one and three months follow-up. In 
order to identify what change each client experienced at each stage, subjects 
were allocated a number from 1 to 12, shown in brackets in Table 5. For instance, 
with regards to subject number 5’s BDI-II scores, he did not achieve a significant 
change at the end of therapy, changed significantly between pre treatment and 
one month follow up, but did not maintain the gains at three months follow-up. 
 
Table 5. Percentages and frequencies of clients achieving a reliable change on the BDI-II, 
BHS and PCOISS across all data collection points (The numbers in brackets identify the 
participants).  
 
  
Reliable Change (RC) 
   
          End Therapy 
n (participants)  
 
 
% 
 
        1 Month FU 
n (participants) 
 
 
% 
 
            3 Month FU 
n (particpants) 
 
 
% 
 
 
BDI-II  
 
 
Significant Change 
desired direction 
 
Significant Change  
opposite direction   
 
Not Significant Change 
 
7(1,2,6,7,9,10,11) 
 
 
0  
 
 
5 (3,4,5,8,12) 
 
58.3 
 
 
0 
 
41.7 
 
7(1,2,5,6,9,10,11) 
 
 
0  
 
 
5 (3,4,7,,8,12) 
 
58.3 
 
 
0 
 
 
41.7 
 
8(1,2,4,6,7,9,10,11) 
 
 
1(8) 
 
 
3 (3,5,12)) 
 
66.7 
 
 
8.3 
 
 
25 
 
BHS 
 
Significant Change 
desired direction:  
 
7 (1,2,5,6,7,10,11) 
 
 
58.3 
 
 
5 (1,5,6, 10,11) 
 
 
41.7 
 
 
7 (1,4,5,6,9,10,11) 
 
 
58.3 
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Significant Change  
opposite direction   
 
Not Sig. Change 
 
1 (9) 
 
 
4 (3,4,8,12) 
 
8.3 
 
 
33.3 
 
3(2,4,7) 
 
 
4 (3,8,9,12) 
 
25 
 
 
33.3 
 
1 (8) 
 
 
4 (2,3,7,12) 
 
8.3 
 
 
33.3 
 
PCOISS 
 
 
Significant Change  
desired direction:  
 
Significant Change  
opposite direction   
 
Not Sig. Change 
 
 
6 (1,2,5,9,10,11) 
 
 
0  
 
 
6 (3,4,6,7,8,12)                
 
 
50 
 
 
0 
 
 
50 
 
7(1,2,5,9,10,11,12) 
 
 
0  
 
 
5 (3,4,6,7,8) 
 
58.3 
 
 
0 
 
 
41.7 
 
8(1,2,5,6,7,9,10,11) 
 
 
0  
 
 
4 (3,4,8,12) 
 
66.7 
 
 
0 
 
 
33.3 
 
 
Return to normal levels of functioning  
 
The second condition of the JT method stipulates that a reliable change will be 
considered clinically significant only if the client’s score at post-test (either at the end 
of therapy, one or three months follow-up) falls within the normal population range 
rather than in the dysfunctional population range. Given the availability of norms for 
both the functional and dysfunctional populations for the BDI-II and the BHS scale, 
criterion ‘c’ has been employed. For the PCOISS only norms for the functional 
population were available, and therefore cut off ‘b’ was used. Clients’ scores at 
post-treatment would have to fall below 14.07 for the BDI-II, below 3.28 for the BHS 
and above 36.6 for the PCOISS for the change to be considered clinically significant. 
The distributions of scores for the relevant outcome measures for both functional and 
dysfunctional populations are summarised in Table 6.   
 
Table 6. Functional and dysfunctional populations according to the cut-offs for BDI-II, BHS and 
PCOISS. 
 
  Range scores  JT cut-off  Functional range  Dysfunctional range 
  
BDI-II   0-63    14.07    0-14.07   > 14.07 
BHS  0-20     3.28    0 -3.28    > 3.28 
PCOISS  0-90     36.6    36.6 -90   < 36.6 
 
 
The number of clients returning to normal levels of functioning, regardless of whether 
or not the change experienced was reliable, is presented in Table 7 below. There are 
some instances when this criteria is not applicable, which happens when the client’s 
score at baseline was already within the functional range. This means that no matter 
how much their scores change in the desirable direction, their change can never be 
clinically significant according to the JT method. This is one of the limitations of this 
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method. One way of addressing this would have been to ensure that at baseline all 
clients’ scores were within the dysfunctional range. This would, however, have the 
disadvantage of excluding clients for treatment, who are dysfunctional in one of the 
other key areas of interest.   
 
Table 7. Percentage and frequencies of clients showing a return to normative levels of 
functioning on the BDI-II, BHS and PCOISS across all data collection points. 
 
 
 
    
             End Therapy 
  
Post test 1 Month FU 
  
Post test 3 Month FU 
 
     n   % n % N % 
 
BDI-II 
 
Criteria Achieved 
 
Criteria Not Achieved  
 
Criteria Not Applicable 
 
5 (1,2,6,10,11) 
 
3 (4,7,9) 
 
4 (3,5,8,12) 
 
41.6 
 
25 
 
33.3 
 
5 (1,2,6,10,11) 
 
3 (4,7,9) 
 
4 (3,5,8,12) 
 
41.6 
 
25 
 
33.3 
 
6 (1,2,6,9,10,11) 
 
2(4,7) 
 
4 (3,5,8,12) 
 
50 
 
16.6 
 
33.3 
 
BHS 
  
Criteria Achieved 
 
Criteria Not Achieved  
 
Criteria Not Applicable 
 
5 (2,5,6,10,11)  
 
6 (1,3,4,7,8,9)  
 
1 (12) 
 
41.7 
 
50 
 
8.33 
 
5 (1,5,6,8,10,12)  
 
6 (2,,3,4,7,9,11)  
 
1 (12) 
 
41.7 
 
50 
 
8.33 
 
6(1,2,5,6,10,11,12) 
 
5(3,4,7,8,9) 
 
1(12) 
 
50 
 
41.7 
 
8.33 
 
PCOISS 
 
Criteria Achieved 
 
Criteria Not Achieved  
 
Criteria Not Applicable 
 
2 (9,11) 
 
2 (4,7)  
 
8(1,2,3,5,6,8,10,12) 
 
16.6 
 
16.6 
 
66.6  
 
3 (7.,9,11) 
 
1 (4) 
 
8(1,2,3,5,6,8,10,12) 
 
25 
 
8.33 
 
66.6 
 
3 (7, 9,11) 
 
1 (4) 
 
8(1,2,3,5,6,8,10,12) 
 
25 
 
8.33 
 
66.6 
 
 
Clinical significance change and categorical ratings  
 
The results of JT’s double fold criteria and the respective categorical rating for each 
individual at the end of therapy, one month follow-up and three months follow-up 
has been summarised in Table 8.  
 
Table 8. Percentage and frequencies of JT’s categorical ratings of clinical improvement 
across phases for the BDI-II, BHS, PCOISS across all data collection points.  
 
  
Therapy Stage 
    
Recovered 
n                              %   
  
 Improved 
n                               % 
  
Unchanged 
n                                % 
 
 Deteriorated 
n                   % 
BDI-II End of Therapy 5 
(1,2,6,10,11) 
41.6 2 
(7,9) 
16.6 5 
(3,4,5,8,12) 
41.6 0 0 
 1 Month FU 5 
(1,2,6,10,11) 
41.6 2 
(9,5) 
16.6 5 
(3,4,7,8,12) 
41.6 0 0 
 3 Month FU 6 
(1,2,6,9,10,11) 
50 2 
(4,7) 
16.6 3 
(3,5,12) 
25 1 
(8) 
8.33 
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BHS End of Therapy 4 
(2,5,,6,10) 
33.3 3 
(1,7,11) 
25 4 
(3,4,8,12) 
33.3 1 
(9) 
8.33 
 1 Month FU 4 
(1,5,6,10) 
33.3 1 
(11) 
 8.3 4 
(3,8,9,12) 
33.3 3 
(2,4,7) 
25 
 3 Month FU 5 
(1,5,6,10,11) 
41.7 2 
(4,9) 
16.6 3 
(2,7,12) 
25 2 
(3,8) 
16.6 
PCOISS End of Therapy 2 
(9,11) 
16.6 4 
(1,2,5,10) 
33.3 6 
(3,4,6,7,8,12) 
50 0 
 
  0 
 1 Month FU 2 
(9,11) 
16.6 5 
(1,2,5,10,12) 
41.6 5 
(3,4,6,7,8) 
41.6 0 
 
  0 
 3 Month FU 3 
(7,9,11) 
25 5 
(1,2,5,6,10) 
41.6 4 
(3,4,8,12) 
33.3 0 
 
  0 
 
Summary of results 
 
The effects of this intervention were measured on depression, mania, hopelessness, 
insight and perceived control of internal states. As indicated in Table 9 below, a 
statistically significant difference for depression and perceived control over internal 
states scores has been found between baseline and both one and three months 
follow up. With regards to the hopelessness scores, the difference between baseline 
and one month follow up was not significant, but this changed when comparing the 
hopelessness scores between baseline and three months follow up. No significant 
differences were found for mania or for level of insight.  
 
Table 9.  Results of statistical analysis  
 
 
 
Depression Mania Hopelessness Insight Perceived Control 
Baseline and  
1 Month FU 
 
Significant 
Large Effect 
Not Significant Not Significant Not Significant Significant 
Large Effect 
 
Baseline and  
3 Month FU 
 
Significant 
Large Effect 
 
Not Significant Significant 
Large Effect 
Not Significant Significant 
Large Effect 
 
The application of the JT method provides information regarding individual variability 
and allows individuals to be classified into categorical ratings for clinical 
improvement. Discussions regarding the change experienced by each client after 
treatment are outside the scope of this article. Table 10 provides a summary of the 
percentages of clients in each category. It should be noted that a considerable 
percentage of clients were found to be Recovered and Improved at one month 
follow up with regards to depression (41.6% and 16.6% respectively), hopelessness 
(33.3% and 8.3%) and perceived control (16.6% and 41.6%) and these figures were 
maintained at three months follow up. These results are consistent with those 
obtained in the statistical analysis. Clients’ scores for mania were unchanged and this 
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confirms the lack of any statistical significance effects. The JT method was not 
applicable to the Insight scale.   
 
Table10. Summary of the percentages of clients in each JT categorical rating for each 
outcome measure  
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1 M 41.6 16.6 41.6 
 
0 0 0 100 0 33.3 8.3 33.3 25 16.6 41.6 41.6 0 
3 M 50 16.6 25 8.3 
 
0 0 100 0 41.6 16.6 25 16.6 25 41.6 33.3 0 
 
Discussion  
 
This study adds to the weight of evidence that short psychological interventions 
based on CBT principles have beneficial effects for clients with BD. The results of both 
the statistical analysis and the application of the JT method indicated that a 
significant reduction in depressive symptoms and an increase in perceived control 
over internal states have been observed following the intervention between baseline 
and one month follow up and between baseline and three months follow-up. 
Significant differences in scores were also found between baseline and three months 
follow-up for hopelessness scores.  
 
As expected, treatment effects were not consistent across measures for the sample 
as a group or with regards to each individual client. It appears that clients with mild 
levels of mania do not benefit from this intervention in terms of reducing their manic 
symptoms, despite every client receiving all the planned components of the 
intervention. This however is not an unusual finding; manic symptoms have shown not 
to respond to other similar interventions (Ball et al., 2006; Scott et al., 2001; Scott et al., 
2006; Lam et al., 2005). 
 
When clients were individually analysed, according to JT’s methodology, a 
substantial proportion of clients were considered not only to have improved, but also 
to have recovered after the treatment intervention with regards to depression, 
perceived control over internal states and hopelessness. A major goal of this study 
was to ascertain the feasibility and acceptability of this intervention when applied by 
a non-expert therapist and the evidence suggests that this four week program for BD 
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clients is not only feasible but acceptable. The acceptability of the program has 
been demonstrated by the very low drop-out rates, the high level of attendance at 
sessions (no clients drop-out after completing session 1) and the clients’ compliance 
with the requirements of the intervention. Treatment acceptability was measured 
through the self-report satisfaction questionnaire (CSQ-8) that clients completed at 
the end of treatment; scores for all 12 clients fell within the ‘High’ satisfaction range 
(27-32). However, the interpretability of these results is questionable given that the 
anonymity was not ensured and the questionnaire was administered by the therapist 
delivering the intervention.  
 
It is not possible to accord a causal role to the treatment intervention for these results, 
however, stability of the behaviour over five weeks at baseline, the immediacy of 
change following the intervention as well as the large magnitude of change 
observed, contribute to the argument that the treatment was responsible for the 
change. Unfortunately, the study did not control for changes in medication or 
frequency of psychiatric outpatient appointments. The main limitations of this study, 
which were partially dictated by practical issues relating to the research funding 
available and time constraints for completion of this project, were the lack of 
statistical power and that clinician delivering the intervention also participated in the 
scoring of instruments.  
 
This is the second study aimed at examining the effects of STIM and the results are 
consistent with those from Sorensen and colleagues (2007) study in which 13 BD 
clients were offered the same intervention by a highly trained clinician. Outcomes 
were collected with regards to level of hopelessness, level of perceived control over 
internal states and satisfaction levels with the same instruments employed in this 
study. Depression, mania and insight were not measured and therefore cannot be 
compared. The follow-up period in the Sorensen and colleagues study was five weeks 
as opposed to one and three months in the present study. The only difference 
between these two studies refers to levels of hopelessness, both studies found a 
significant effect on BHS, but whereas Sorensen and colleagues (2007) observed a 
significant difference between baseline and one week post treatment and at five 
weeks follow up, this result was not replicated in this study. The present study found no 
significant differences at one month follow-up, but the differences between baseline 
and three months were statistically significant.  Both studies identified a statistically 
significant difference for perceived control between baseline and each follow-up 
point (one and five weeks for Sorensen, one and three months for the current study). 
In considering what may account for the differences between these two studies, one 
should refer to the different levels of expertise of the clinician and to random variation 
in small samples.   
  
Europe’s Journal of Psychology 
 
 
353 
The main implication of this study is that the positive results obtained on depression, 
hopelessness and perceived control, coupled with the fact that this is a very short 
intervention requiring little training on the part of the clinician, together with the high 
levels of acceptability from clients, provide enough support for this type of treatment 
to be provided to a larger population. The present study should be replicated with 
larger samples and appropriate controls. It will be important to include longer follow 
up periods to determine whether or not the results are maintained over a longer 
course. In order to be able to compare this intervention to those more complex and 
widely researched, one needs to include a survival analysis. The primary measure 
against which the efficacy of an intervention in BD is measured is time to first relapse 
and whether the current reduction in symptoms, reduced levels of hopelessness and 
increase perceived control translate in lower relapse rates and longer time without 
relapse remains to be seen. 
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